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with the standard ﬁve years of tamoxifen treatment, with addi-
tional costs per QALY gained.
PCN16
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OBJECTIVES: To identify cost consequences and cost effective-
ness of R-MCP (rituximab, mitoxantrone, chlorambucil, pred-
nisolone) vs. MCP from the perspective of a third party payer in
Germany (statutory sickness fund). METHODS: Resource uti-
lization data on 329 patients were collected in parallel to a RCT
and analyzed for the treatment phase (8 months). In addition,
an interim analysis of the subsequent observation period was
conducted. Data for initial chemotherapy, chemotherapy admin-
istration, treatment of adverse events, treatment of complica-
tions/progressive disease, subsequent chemotherapies, and
treatment for other reasons were collected. Several sensitivity
analyses were performed to address different cost environments
and discounting scenarios. RESULTS: Mean cost of the treat-
ment phase in the base case analysis was €35,600 for R-MCP
and €21,500 MCP per patient (p < 0.0001). More treatment
cycles were administered in the R-MCP arm (1026 MCP, 1237
R-MCP). Mean cost per patient and active treatment cycle was
€4900 for R-MCP and €3300 for MCP (p < 0.0002). Mean
observation period after end of initial treatment were 26.9
months for R-MCP and 25.8 months for MCP. Costs for treat-
ment of adverse events, new chemotherapies, treatment of pro-
gressive disease and other reasons was substantially reduced in
the R-MCP arm. This resulted in mean (undiscounted) cost per
patient in the observation period of €17,900 for R-MCP and
€30,700 for MCP (p < 0.01). Overall costs were €51,100 for R-
MCP and €53,900 for MCP (p = 0.6). Clinically, R-MCP resulted
in statistically signiﬁcant superior response rate, event free sur-
vival and overall survival. CONCLUSION: Initially higher treat-
ment costs of R-MCP were compensated by savings due to
reduced toxicity and better efﬁcacy after slightly more than two
years. Combined with the clinical superiority of R-MCP, this
regime is likely to prevail as the dominant treatment strategy
compared to MCP alone at the ﬁnal analysis (at four years 
observation).
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OBJECTIVES: Cetuximab in combination with irinotecan
(cet/iri) is a new chemotherapy option for patients with EGFR-
expressing metastatic colorectal cancer after failure of irinote-
can-including cytotoxic therapy. In Scotland, the prognosis for
patients with metastatic colorectal cancer (mCRC) is poor and
there are limited therapy options after the failure of conventional
cytotoxic agents. Our objective was to determine the incremen-
tal cost-effectiveness of cet/iri compared to current practice in
Scotland. METHODS: Given there are no licensed treatment
options for this patient group in Scotland, the economic evalua-
tion compared cet/iri with best/active supportive care (ASC). The
perspective of the economic evaluation was that of the National
Health Service in Scotland. The economic evaluation was based
on a pivotal clinical trial comparing cetuximab in combination
with irinotecan with cetuximab monotherapy (BOND). As the
BOND study did not directly compare cet/iri with ASC, the data
were ‘bridged’ to estimate overall survival. Sensitivity analyses
are presented by way of both probabilistic analysis and univari-
ate sensitivity analysis. RESULTS: Data from the BOND study
showed median time to disease progression (TTP) is signiﬁcantly
longer with cet/iri, 4.1 months, than cetuximab alone, 1.5
months. Median survival was 8.6 months for cet/iri and 6.9
months for cetuximab. In our evaluation, estimated mean overall
survival was 10.8 months for cet/iri and 5.6 months for ASC.
Over the duration of the economic model, cet/iri patients
incurred additional costs of £13,851 and gained additional 0.42
life-years per patient compared with ASC patients. The incre-
mental cost per life-year gained for cet/iri versus ASC was
£32,752. The incremental cost per QALY gained was £34,454.
CONCLUSIONS: Cet/iri is an effective chemotherapy option for
mCRC patients failing conventional cytotoxic agents and who
have limited therapy options. Our study shows that cet/iri is also
within the range of acceptable cost-effectiveness when compared
to other oncology therapies.
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OBJECTIVES: Although tamoxifen shows beneﬁt in the ﬁrst ﬁve
years of adjuvant therapy, extending its use by an additional ﬁve
years is not beneﬁcial. This has created an unmet medical need
for patients who are disease free after 5 years of standard adju-
vant therapy, but still have a signiﬁcant risk of relapse over the
following ten years. In a large randomized placebo-controlled
trial, letrozole signiﬁcantly reduced the risk of recurrence by
42% and the risk of distant metastases by 39%. The DFS was
signiﬁcantly improved with letrozole regardless of nodal status.
METHODS: A Markov model was developed to evaluate the
lifetime cost-utility of extended adjuvant letrozole in post-
menopausal women. The cost-utility analysis was based on the
results of the MA17 trial, from which patient-level data was used
to estimate event rates in both treatment groups. Expected costs,
life-years and QALYs were estimated by summing across all
health states and cycles for each treatment group. Deterministic
and probabilistic sensitivity analyses were performed to account
for uncertainty. RESULTS: The baseline results from the model
show ICERs of $30,100/LY and $34,058/QALY for a cohort of
1000 postmenopausal women. Letrozole is even more cost-effec-
tive in the node positive patient sub-group than for the aggre-
gate patient group, with an incremental cost per life-year of
$23,235 and an incremental cost per QALY of $26,553. For
node negative patients the model shows ICERs of $41,357 per
life-year and an incremental cost per QALY of $46,049. The sen-
sitivity analyses show narrow ranges for the credible intervals,
and for a threshold of $50,000/QALY the likelihood that letro-
zole would be cost-effective is 1.0 in node positive patients, while
being 0.77 in node negative patients. CONCLUSION: Our
model shows that letrozole is cost-effective in both node nega-
tive and node positive patients with ICERs far below the gener-
ally accepted threshold of $50,000/QALY.
